Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective,...

Area of Science:

• Hematology
• Pediatric Medicine
• Pharmacology

Background:

• Established clinical efficacy of hydroxyurea for sickle cell anemia (SCA).
• Limited data on hydroxyurea's real-world effectiveness in pediatric SCA patients.
• Need to assess hydroxyurea's impact on healthcare utilization and clinical outcomes in a large pediatric cohort.

Purpose of the Study:

• To evaluate the clinical effectiveness of hydroxyurea in a large pediatric population with SCA.
• To compare healthcare utilization and clinical outcomes before and after hydroxyurea initiation.
• To control for disease severity selection bias using a retrospective cohort, pre-post treatment design.

Main Methods:

• Retrospective cohort study of pediatric patients with SCA (SS, Sβ⁰ thalassemia) initiating hydroxyurea between 2009-2011.
• Exclusion criteria included chronic transfusions, inadequate follow-up, or prior hydroxyurea use.
• Comparison of healthcare utilization (hospitalizations, ED visits, pain encounters) and laboratory values (hemoglobin) for 2 years pre- and post-hydroxyurea initiation.

Main Results:

• Hydroxyurea initiation led to significant reductions: 47% in hospitalizations, 36% in pain encounters, and 43% in emergency department visits.
• Average hemoglobin levels increased by 0.7 g/dL.
• Effectiveness was consistent across gender, insurance, and age groups, with a trend towards greater hospitalization reduction in younger children.

Conclusions:

• Hydroxyurea is clinically effective in managing pediatric sickle cell anemia in a real-world setting.
• The treatment significantly reduces healthcare utilization and improves hematological parameters.
• Findings support the use of hydroxyurea as a key therapeutic option for children with SCA.